Stock Events

Stock Events

ABLIVA AB 

$0.03
5
+$0+0% Thursday 15:03

Statistics

Day High
0.03
Day Low
0.03
52W High
0.03
52W Low
0.03
Volume
58,900
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

22MayExpected
Q2 2022
Q3 2022
Q1 2024
Q2 2024
Q3 2024
Q4 2024
Q1 2025
-0
-0
-0
-0
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-14.21MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NEVPF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for rare neuromuscular diseases, similar to Abliva's focus on mitochondrial diseases.
PTC Therapeutics
PTCT
Mkt Cap5.4B
PTC Therapeutics is involved in the development of genetically targeted therapies for rare diseases, overlapping with Abliva's patient population.
Biogen
BIIB
Mkt Cap22.63B
Biogen develops therapies for neurological and neurodegenerative diseases, competing in the broader market for treatments of conditions similar to those targeted by Abliva.
Ionis Pharmaceuticals
IONS
Mkt Cap12.03B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery, which competes with Abliva's approach to treating mitochondrial diseases.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals works on RNA interference (RNAi) therapeutics for rare genetic diseases, a similar field to Abliva's focus.
Ultragenyx Pharmaceutical
RARE
Mkt Cap3.33B
Ultragenyx Pharmaceutical targets rare and ultra-rare diseases with its drug development, including genetic disorders that may overlap with Abliva's mitochondrial disease focus.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical develops enzyme replacement therapies for rare genetic disorders, potentially competing with Abliva's treatments for mitochondrial dysfunction.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is known for its work on cystic fibrosis, but its interest in expanding into other rare diseases could position it as a competitor to Abliva.
AMGEN
AMGN
Mkt Cap160.66B
Amgen, a biotech giant, has a broad focus that includes treatments for rare diseases, which could encompass areas competitive with Abliva's niche.
Novartis
NVS
Mkt Cap237.61B
Novartis AG, through its extensive research and development in healthcare, including treatments for neurological conditions, could potentially compete with Abliva in the mitochondrial disease space.

About

Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Show more...
CEO
Dr. Ellen K. Donnelly Ph.D.
Employees
6
Country
SE

Listings

0 Comments

Share your thoughts

FAQ

What is ABLIVA AB stock price today?▼
The current price of NEVPF is $0.03 USD — it has increased by +0% in the past 24 hours. Watch ABLIVA AB stock price performance more closely on the chart.
What is ABLIVA AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange ABLIVA AB stocks are traded under the ticker NEVPF.
What is ABLIVA AB revenue for the last year?▼
ABLIVA AB revenue for the last year amounts to 0 USD.
What is ABLIVA AB net income for the last year?▼
NEVPF net income for the last year is -14.21M USD.
How many employees does ABLIVA AB have?▼
As of April 01, 2026, the company has 6 employees.
In which sector is ABLIVA AB located?▼
ABLIVA AB operates in the Health Care sector.
When did ABLIVA AB complete a stock split?▼
ABLIVA AB has not had any recent stock splits.
Where is ABLIVA AB headquartered?▼
ABLIVA AB is headquartered in Lund, SE.